BR112016013874A2 - Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica - Google Patents
Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêuticaInfo
- Publication number
- BR112016013874A2 BR112016013874A2 BR112016013874A BR112016013874A BR112016013874A2 BR 112016013874 A2 BR112016013874 A2 BR 112016013874A2 BR 112016013874 A BR112016013874 A BR 112016013874A BR 112016013874 A BR112016013874 A BR 112016013874A BR 112016013874 A2 BR112016013874 A2 BR 112016013874A2
- Authority
- BR
- Brazil
- Prior art keywords
- triazole
- intermediates
- pyridine
- phenyl
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
FENIL-TRIAZOLO-PIRIDINA, SEUS USOS, SEUS PROCESSO DE PRODUÇÃO E SEUS INTERMEDIÁRIOS, E COMPOSIÇÃO FARMACÊUTICA. A presente invenção fornece um composto da fórmula I abaixo: em que R(1) é selecionado do grupo que consiste em H, CH(3), CN, -CH(2)CN, -C(CH(3))(2)CN, F, Cl, e Br; R(2) é selecionado do grupo que consiste em H, -O(C(1)-C(3) alquileno)R(4), -CH(2) CN, CN, -OCH(3), CF(2), -C(CH(3))(2) CN, -C(CH(3))(2), -S(O)(2) CH(3), -S(O)(2) NH(2), e -OCF(2); R(3) é selecionado do grupo que consiste em H, CH(3), e -OCH(3); e R(4) é selecionado do grupo que consiste em H, -C(CH(3))(2) CN, -OCH(3), -S(O)(2) CH(3), CN, e -C(CH(3))(2) OH; ou um sal farmacêutico do mesmo, métodos de tratamento de dois tipos de diabetes usando o composto e um processo para preparação do composto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925802P | 2014-01-10 | 2014-01-10 | |
| PCT/US2015/010291 WO2015105786A1 (en) | 2014-01-10 | 2015-01-06 | Phenyl-triazolo-pyridine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016013874A2 true BR112016013874A2 (pt) | 2017-08-08 |
Family
ID=52440835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016013874A BR112016013874A2 (pt) | 2014-01-10 | 2015-01-06 | Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9617263B2 (pt) |
| EP (1) | EP3092241B1 (pt) |
| JP (1) | JP6211200B2 (pt) |
| KR (1) | KR20160095117A (pt) |
| CN (1) | CN105873929B (pt) |
| AU (1) | AU2015204923A1 (pt) |
| BR (1) | BR112016013874A2 (pt) |
| CA (1) | CA2931822A1 (pt) |
| EA (1) | EA201691071A1 (pt) |
| ES (1) | ES2653425T3 (pt) |
| MX (1) | MX2016008910A (pt) |
| WO (1) | WO2015105786A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016012469A2 (pt) | 2014-01-10 | 2017-08-08 | Lilly Co Eli | Isopropil triazolo piridina, seus usos, seu processo de preparação e seus intermediários, composição farmacêutica |
| US11964938B2 (en) | 2018-01-08 | 2024-04-23 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
| TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| EP4234030A3 (en) | 2018-07-13 | 2023-10-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2021013742A1 (en) * | 2019-07-19 | 2021-01-28 | Janssen Pharmaceutica Nv | 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN115317484B (zh) * | 2022-08-26 | 2023-07-18 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用 |
| CN115671105B (zh) * | 2022-11-22 | 2023-10-27 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗肾脏疾病药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
| AU2005220728B2 (en) | 2004-02-27 | 2009-08-06 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| US8530413B2 (en) * | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| US9271969B2 (en) | 2012-02-07 | 2016-03-01 | Kainos Medicine, Inc. | Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| TW201609722A (zh) * | 2013-12-13 | 2016-03-16 | 美國禮來大藥廠 | 新穎三唑并吡啶化合物 |
| BR112016012469A2 (pt) | 2014-01-10 | 2017-08-08 | Lilly Co Eli | Isopropil triazolo piridina, seus usos, seu processo de preparação e seus intermediários, composição farmacêutica |
-
2015
- 2015-01-06 MX MX2016008910A patent/MX2016008910A/es unknown
- 2015-01-06 EP EP15702019.9A patent/EP3092241B1/en active Active
- 2015-01-06 CA CA2931822A patent/CA2931822A1/en not_active Abandoned
- 2015-01-06 EA EA201691071A patent/EA201691071A1/ru unknown
- 2015-01-06 BR BR112016013874A patent/BR112016013874A2/pt not_active IP Right Cessation
- 2015-01-06 ES ES15702019.9T patent/ES2653425T3/es active Active
- 2015-01-06 AU AU2015204923A patent/AU2015204923A1/en not_active Abandoned
- 2015-01-06 WO PCT/US2015/010291 patent/WO2015105786A1/en active Application Filing
- 2015-01-06 US US15/106,998 patent/US9617263B2/en active Active
- 2015-01-06 KR KR1020167018137A patent/KR20160095117A/ko active Search and Examination
- 2015-01-06 JP JP2016544801A patent/JP6211200B2/ja active Active
- 2015-01-06 CN CN201580004127.3A patent/CN105873929B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9617263B2 (en) | 2017-04-11 |
| EP3092241B1 (en) | 2017-10-04 |
| JP6211200B2 (ja) | 2017-10-11 |
| AU2015204923A1 (en) | 2016-06-09 |
| WO2015105786A1 (en) | 2015-07-16 |
| ES2653425T3 (es) | 2018-02-07 |
| KR20160095117A (ko) | 2016-08-10 |
| CN105873929A (zh) | 2016-08-17 |
| CN105873929B (zh) | 2018-04-06 |
| CA2931822A1 (en) | 2015-07-16 |
| EP3092241A1 (en) | 2016-11-16 |
| MX2016008910A (es) | 2016-10-04 |
| US20170029420A1 (en) | 2017-02-02 |
| JP2017503800A (ja) | 2017-02-02 |
| EA201691071A1 (ru) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016013874A2 (pt) | Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica | |
| BR112018076600A2 (pt) | processo para a preparação de derivado de piridona policíclica substituída e cristal do mesmo | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| BR112018005194A2 (pt) | processo de composto antifúngico | |
| BR112016012123A8 (pt) | composto de triazolo-piridina | |
| BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
| EA201591382A1 (ru) | Ингибиторы гистондеметилаз | |
| BR112017009701A2 (pt) | composto e métodos para a preparação de um composto | |
| BR112016012469A2 (pt) | Isopropil triazolo piridina, seus usos, seu processo de preparação e seus intermediários, composição farmacêutica | |
| CO2017005959A2 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| BR112015004029A2 (pt) | Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| BR112014003079A2 (pt) | derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes | |
| AR090596A1 (es) | Formulaciones farmaceuticas que comprenden antagonistas de ccr3 | |
| AR100694A1 (es) | Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| BR112017000821A2 (pt) | novos compostos de pirimidina substituída. | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| BR112017000830A2 (pt) | novas 2,5-piridinas substituídas | |
| BR112017005299A2 (pt) | inibidores de lrrk2 cinase macrocíclicos | |
| BR112016013618A8 (pt) | derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
| BR112016000968A2 (pt) | Processo para a preparação de bifenilanilidas halogenadas | |
| BR112014018712A8 (pt) | Derivados de morfolinila úteis como inibidores de mogat-2 | |
| BR112017000826A2 (pt) | novas 2,5-piridinas substituídas. | |
| BR112016018418A2 (pt) | Composto, uso do mesmo, e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |